JP2023520636A5 - - Google Patents

Info

Publication number
JP2023520636A5
JP2023520636A5 JP2022555860A JP2022555860A JP2023520636A5 JP 2023520636 A5 JP2023520636 A5 JP 2023520636A5 JP 2022555860 A JP2022555860 A JP 2022555860A JP 2022555860 A JP2022555860 A JP 2022555860A JP 2023520636 A5 JP2023520636 A5 JP 2023520636A5
Authority
JP
Japan
Prior art keywords
amino acid
seq
chain variable
variable region
bispecific
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022555860A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023520636A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/022626 external-priority patent/WO2021188590A2/en
Publication of JP2023520636A publication Critical patent/JP2023520636A/ja
Publication of JP2023520636A5 publication Critical patent/JP2023520636A5/ja
Pending legal-status Critical Current

Links

JP2022555860A 2020-03-16 2021-03-16 T細胞二重特異性結合タンパク質 Pending JP2023520636A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062990281P 2020-03-16 2020-03-16
US62/990,281 2020-03-16
PCT/US2021/022626 WO2021188590A2 (en) 2020-03-16 2021-03-16 T-cell bispecific binding proteins

Publications (2)

Publication Number Publication Date
JP2023520636A JP2023520636A (ja) 2023-05-18
JP2023520636A5 true JP2023520636A5 (cg-RX-API-DMAC7.html) 2024-03-21

Family

ID=77768281

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022555860A Pending JP2023520636A (ja) 2020-03-16 2021-03-16 T細胞二重特異性結合タンパク質

Country Status (7)

Country Link
US (1) US20230183344A1 (cg-RX-API-DMAC7.html)
EP (1) EP4121462A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023520636A (cg-RX-API-DMAC7.html)
CN (1) CN115667314A (cg-RX-API-DMAC7.html)
AU (1) AU2021239929A1 (cg-RX-API-DMAC7.html)
CA (1) CA3171709A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021188590A2 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019217942A1 (en) 2018-05-11 2019-11-14 Beam Therapeutics Inc. Methods of substituting pathogenic amino acids using programmable base editor systems
JP7137696B2 (ja) 2019-05-14 2022-09-14 プロヴェンション・バイオ・インコーポレイテッド 1型糖尿病を予防するための方法および組成物
KR20230092863A (ko) 2020-06-11 2023-06-26 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
MX2023013851A (es) 2021-05-24 2023-12-08 Provention Bio Inc Metodos para el tratamiento de diabetes tipo 1.
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2024131861A1 (en) * 2022-12-21 2024-06-27 Erasmus University Medical Center Rotterdam Bispecific antibodies targeting cd117 and cd3
EP4719352A1 (en) 2023-05-31 2026-04-08 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
CN119241716B (zh) * 2024-09-13 2026-05-19 杭州百瑞竞康生物技术有限公司 结合CD235a和CD3的融合蛋白及其制备方法和用途
CN119874942B (zh) * 2025-03-28 2025-09-26 核欣(苏州)医药科技有限公司 一种放射性蛋白偶联药物及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE050159T2 (hu) * 2013-12-17 2020-11-30 Genentech Inc Anti-CD3 antitestek és alkalmazási eljárások
EP3105252B1 (en) * 2014-02-12 2019-07-24 Michael Uhlin Bispecific antibodies for use in stem cell transplantation
ES2823033T3 (es) * 2015-05-28 2021-05-05 Genentech Inc Ensayo basado en células para detectar homodímeros anti-CD3
TWI796283B (zh) * 2015-07-31 2023-03-21 德商安美基研究(慕尼黑)公司 Msln及cd3抗體構築體
IL258491B2 (en) * 2015-10-16 2023-09-01 Univ Columbia Preparations and methods for inhibiting antigens of a particular lineage
EP3408671B1 (en) * 2016-01-25 2023-11-01 F. Hoffmann-La Roche AG Methods for assaying t-cell dependent bispecific antibodies
US10538579B2 (en) * 2016-08-15 2020-01-21 Board Of Regents, The University Of Texas System Bispecific pertussis antibodies
TWI687227B (zh) * 2017-10-03 2020-03-11 生倍科技股份有限公司 用於t細胞免疫療法之組合及其用途
US10882915B2 (en) * 2017-10-24 2021-01-05 Magenta Therapeutics, Inc. Compositions and methods for the depletion of CD117+ cells
EP3700568A4 (en) * 2017-10-24 2021-11-10 Magenta Therapeutics, Inc. COMPOSITIONS AND METHODS FOR DEPLOYING CD117 + CELLS
WO2019084053A1 (en) * 2017-10-24 2019-05-02 Magenta Therapeutics, Inc. COMPOSITIONS AND METHODS FOR DEPLOYING CD117 + CELLS
CN113330026A (zh) * 2018-10-23 2021-08-31 美真达治疗公司 Fc沉默的抗体药物缀合物(ADC)及其用途
GB201912681D0 (en) * 2019-09-04 2019-10-16 Eth Zuerich Bispecific binding agent that binds to cd117/c-kit and cd3

Similar Documents

Publication Publication Date Title
JP2022531141A5 (cg-RX-API-DMAC7.html)
US20230028110A1 (en) Anti-tcr delta variable 1 antibodies
US20230183344A1 (en) T-cell bispecific binding proteins
EP4269444B1 (en) Multispecific anti-tcr delta variable 1 antibodies
US20220403025A1 (en) Therapeutic uses of anti-tcr delta variable 1 antibodies
JP2023515199A5 (cg-RX-API-DMAC7.html)
JP2023515199A (ja) 免疫応答を調節するための材料及び方法
JP2022521850A5 (cg-RX-API-DMAC7.html)
US20210284731A1 (en) Methods and materials for modulating an immune response
JP2025507836A5 (cg-RX-API-DMAC7.html)
SG11202107474RA (en) Anti-tigit antibodies
JP2025507836A (ja) 骨髄コンディショニング方法
Kobayashi et al. Improved Biodistribution of 125I-labeled Anti-Tac Disulfide-stabilized Fv Fragment by Blocking Its Binding to the α Subunit of the Interleukin 2 Receptor in the Circulation with Preinjected Humanized Anti-Tac IgG
EP4110390A1 (en) Materials and methods for modulating an immune response
HK40103002A (en) Multispecific anti-tcr delta variable 1 antibodies
HK40103002B (en) Multispecific anti-tcr delta variable 1 antibodies
HK40103226A (en) Multispecific anti-tcr delta variable 1 antibodies
HK40097714A (en) Multispecific anti-tcr delta variable 1 antibodies
HK40102396A (en) Multispecific anti-tcr delta variable 1 antibodies
WO2024152962A1 (zh) 抗tt3的人源化抗体及其应用
HK40103477A (en) Multispecific anti-tcr delta variable 1 antibodies
HK40102395B (en) Multispecific anti-tcr delta variable 1 antibodies
HK40102395A (en) Multispecific anti-tcr delta variable 1 antibodies